Literature DB >> 10785632

Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria.

H Smith1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10785632     DOI： 10.1016/s0966-842x(00)01755-8

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


× No keyword cloud information.
  11 in total

1.  Assembly and disassembly kinetics of anthrax toxin complexes.

Authors:  Kenneth A Christensen; Bryan A Krantz; R John Collier
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

2.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

Review 3.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

Review 4.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

5.  Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.

Authors:  Benedikt A Aulinger; Michael H Roehrl; John J Mekalanos; R John Collier; Julia Y Wang
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  AMPD3 is involved in anthrax LeTx-induced macrophage cell death.

Authors:  Sangun Lee; Yanhai Wang; Sung Ouk Kim; Jiahuai Han
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

7.  EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin.

Authors:  Quan Lu; Wensheng Wei; Paul E Kowalski; Annie C Y Chang; Stanley N Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

8.  Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Authors:  Sha Cao; Aizhen Guo; Ziduo Liu; Yadi Tan; Gaobing Wu; Chengcai Zhang; Yaxing Zhao; Huanchun Chen
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

9.  The anthrax toxin channel: a barrel of LFs.

Authors:  Robert O Blaustein
Journal:  J Gen Physiol       Date:  2011-03-14       Impact factor: 4.086

10.  Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin.

Authors:  Julia Y Wang; Michael H Roehrl
Journal:  Med Immunol       Date:  2005-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.